Novartis presents promising new data on treatment for relapsing MS

Data showed that continuous treatment with Kesimpta was associated with fewer relapses and reduced risk of disability worsening
Novartis has presented new data that demonstrates the long-term efficacy and safety of its monoclonal antibody Kesimpta (ofatumumab) in people living with relapsing multiple sclerosis following up to four years of treatment.
The long-term data comes from the company's Phase 3 Asclepios I/II trials and Alithios open-label extension. Kesimpta maintained a similar safety profile as seen in Phase 3 trials, with no new safety risks identified over the four-year treatment period.
Kesimpta was approved by the US Food and Drug Administration (FDA) in August, 2020.
Multiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system characterized by myelin destruction and axonal damage in the brain, optic nerves and spinal cord. It affects approximately 2.3 million people worldwide. Relapsing MS is a form of the disease where patients have relapses (symptoms worsen) and periods of stability in between relapses.
In addition to demonstrating efficacy with four years of continuous treatment with Kesimpta, participants who switched from teriflunomide, an oral medication, to Kesimpta in the extension phase saw significant reductions in relapses and MRI lesions.
Novartis Global Medical Franchise Head, Lykke Hinsch Gylvin, said the data supports Kesimpta as an “efficacious and well-tolerated" option for people living with relapsing MS.
She said: “The sustained reductions in disability progression and lesion activity observed in those receiving continuous Kesimpta versus those who switched later from teriflunomide highlight the value of earlier treatment initiation with Kesimpta”.
Additionally, data from the ongoing KYRIOS open-label, prospective study shows that people taking Kesimpta for MS can mount an immune response to mRNA COVID-19 vaccines. All participants in the study who were vaccinated during continuous Kesimpta treatment developed an immune response as soon as one week after initial vaccination.
The FDA has approved more than a dozen medications for the treatment of relapsing forms of MS, which include clinically isolated syndrome, relapsing-remitting disease and active secondary progressive disease.
Related News
-
News A Day in the Life of a Vice President of Business Development
In this month's Day in the Life Of interview, I spoke to Nigel Stapleton, VP of Business Development in Biopharmaceutical Contract Manufacturing for Mabion SA, about his illustrious career and some personal highlights. -
News Pharmaceutical Packaging Market Prospects: Shifting regional policies
The pharmaceutical packaging industry is experiencing significant transformation in 2025, driven by regulatory changes, supply chain challenges, and sustainability initiatives. The US BIOSECURE Act, passed through the House of Representatives in Septem... -
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News China import tax fine could cost AstraZeneca up to US$8 million
British-Swedish drugmaker AstraZeneca could find itself facing fines of up to US$8million in China due to suspected unpaid import taxes on breast cancer drug Enhertu.
-
News Women in Pharma: Building from the ground up together
Our monthly Women in Pharma series highlights the influential lives and works of impactful women working across the pharmaceutical industry, and how the industry can work towards making the healthcare industry and workplace more equitable and inclusive... -
News Pharmaceutical Packaging Market Prospects – Innovations in Packaging and Drug Delivery
Download the Pharmaceutical Packaging Market Prospects Trend Report to explore the full report and delve into the evolving opportunities in pharmaceutical packaging and drug delivery. -
News Novartis to invest US$23 billion in US facilities amid tariff threats
Swiss pharmaceutical giant Novartis has announced its intention to invest up to US$23 billion in building and expanding ten pharmaceutical facilities in the US as drugmakers scramble to respond to potential drug import and manufacturing tariffs declare... -
News CPHI Podcast Series: Fulfilling an unmet need for rare disease patients
Our April episode from the CPHI Podcast Series is looking into rare diseases, and more specifically how pharmaceutical companies can better support this smaller population of rare disease patients.